Discover a New Class of Non-Opioid, Oral Drugs to Treat Pain
Chronic pain is estimated to affect approximately 100 million Americans, but safe and effective treatment options for pain management are currently insufficient. Patients with pain are often prescribed opioids and other drugs that have common and potentially serious side effects such as drowsiness, impaired ability to focus and, in some cases, potential for addiction.
At EicOsis, we are responding to this unmet need for effective and safe treatments for pain by developing a new class of analgesics that can provide pain relief without the undesirable side effects of currently available drugs. EC5026 is our first human drug candidate.
EC5026 is a First-in-Class, Non-Opioid, Oral Analgesic
Our lead drug, EC5026, targets acute and chronic pain arising from a wide range of medical conditions. EC5026 addresses the urgent need for a safer, non-addictive, effective analgesic and has been advanced to first-in-human clinical trials in December 2019.
EC5026 Works by Increasing the Levels of Natural Analgesic and Anti-Inflammatory Molecules
EC5026 regulates the activity of powerful analgesic and anti-inflammatory fatty acids called epoxyeicosatrienoic acids (EETs) that are present in all cells in humans and animals. EC5026 inhibits the soluble epoxide hydrolase (sEH) enzyme, responsible of rapidly eliminating EETs. By inhibiting sEH, EC5026 increases the levels of EET levels at high anti-inflammatory and analgesic levels for 24 hours or longer. EC5026 is a very potent molecule designed for once daily oral dosing.
EC5026 Has Been Studied in Standard Preclinical Studies
Preclinical studies suggest that sEH inhibitors can decrease pain and inflammation and do not appear to produce sedation, cognitive dysfunction or other side effects common to currently available analgesics.
Phase 1a First-in-Human Clinical Trials of EC5026 Started in December 2019
EicOsis received IND clearance from the FDA for EC5026 in October 2019. Phase 1a clinical trials in human volunteers started in December 2019. Phase 1b clinical trials are planned for the Summer of 2020.